127 related articles for article (PubMed ID: 21627327)
1. Structure-based fragment hopping for lead optimization using predocked fragment database.
Lin FY; Tseng YJ
J Chem Inf Model; 2011 Jul; 51(7):1703-15. PubMed ID: 21627327
[TBL] [Abstract][Full Text] [Related]
2. LeadOp+R: Structure-Based Lead Optimization With Synthetic Accessibility.
Lin FY; Esposito EX; Tseng YJ
Front Pharmacol; 2018; 9():96. PubMed ID: 29556192
[TBL] [Abstract][Full Text] [Related]
3. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
Hoffer L; Renaud JP; Horvath D
J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
[TBL] [Abstract][Full Text] [Related]
4. Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.
Liu Q; Masek B; Smith K; Smith J
J Med Chem; 2007 Nov; 50(22):5392-402. PubMed ID: 17918924
[TBL] [Abstract][Full Text] [Related]
5. E-novo: an automated workflow for efficient structure-based lead optimization.
Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
[TBL] [Abstract][Full Text] [Related]
6. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking.
Kolb P; Caflisch A
J Med Chem; 2006 Dec; 49(25):7384-92. PubMed ID: 17149868
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based discovery of focal adhesion kinase inhibitors.
Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
[TBL] [Abstract][Full Text] [Related]
8. Fragment-based de novo ligand design by multiobjective evolutionary optimization.
Dey F; Caflisch A
J Chem Inf Model; 2008 Mar; 48(3):679-90. PubMed ID: 18307332
[TBL] [Abstract][Full Text] [Related]
9. A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes.
Köster H; Craan T; Brass S; Herhaus C; Zentgraf M; Neumann L; Heine A; Klebe G
J Med Chem; 2011 Nov; 54(22):7784-96. PubMed ID: 21972967
[TBL] [Abstract][Full Text] [Related]
10. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
Lange G; Lesuisse D; Deprez P; Schoot B; Loenze P; Bénard D; Marquette JP; Broto P; Sarubbi E; Mandine E
J Med Chem; 2003 Nov; 46(24):5184-95. PubMed ID: 14613321
[TBL] [Abstract][Full Text] [Related]
11. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
12. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
[TBL] [Abstract][Full Text] [Related]
13. Automatic tailoring and transplanting: a practical method that makes virtual screening more useful.
Li Y; Zhao Y; Liu Z; Wang R
J Chem Inf Model; 2011 Jun; 51(6):1474-91. PubMed ID: 21520918
[TBL] [Abstract][Full Text] [Related]
14. Selection of fragments for kinase inhibitor design: decoration is key.
Czodrowski P; Hölzemann G; Barnickel G; Greiner H; Musil D
J Med Chem; 2015 Jan; 58(1):457-65. PubMed ID: 25437144
[TBL] [Abstract][Full Text] [Related]
15. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors.
Kolb P; Kipouros CB; Huang D; Caflisch A
Proteins; 2008 Oct; 73(1):11-8. PubMed ID: 18384152
[TBL] [Abstract][Full Text] [Related]
16. Improving VEGFR-2 docking-based screening by pharmacophore postfiltering and similarity search postprocessing.
Planesas JM; Claramunt RM; Teixidó J; Borrell JI; Pérez-Nueno VI
J Chem Inf Model; 2011 Apr; 51(4):777-87. PubMed ID: 21417262
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
18. Electron density guided fragment-based drug design--a lead generation example.
Abad MC; Gibbs AC; Zhang X
Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
[TBL] [Abstract][Full Text] [Related]
19. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
20. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
